Business, energy, technology, markets and global industry news from Business News Today

in vivo CAR-T

PharmaDeviceNews in vivo CAR-T
Sail Biomedicines’ in vivo CAR-T collaboration with Johnson & Johnson highlights growing investment in RNA-based immune-cell therapies for autoimmune diseases. Representative image.
Pharma & Biotech

Why Johnson & Johnson is staking $785m on Sail’s in vivo CAR-T platform before human trials

Johnson & Johnson backs Sail Biomedicines’ in vivo CAR-T platform with $785 million in initial payments and a $2.58 billion buyout option.

Read More
Representative image of researchers working in a modern cell therapy laboratory, reflecting T-CURX’s acquisition of Pantherna Therapeutics and the growing race to advance in vivo CAR-T, mRNA delivery and lipid nanoparticle technologies.
Pharma & Biotech

Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing

T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.

Read More
Representative image of circular RNA-based in vivo CAR-T research in a biotechnology laboratory, highlighting Therorna’s TI-0032 program and the growing push to make cell therapy more scalable for autoimmune disease treatment.
Pharma & Biotech

Could Therorna’s circRNA in vivo CAR-T platform change autoimmune disease treatment?

CAR-T is powerful but hard to scale. Therorna’s circRNA platform tests whether in vivo engineering can move the field beyond bespoke therapy.

Read More
Pharma & Biotech

What Lilly’s Orna Therapeutics deal means for immune reset strategies

Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, Inc., gaining access to the biotechnology firm’s circular RNA platform and its clinical trial ready in vivo CAR-T candidate ORN-252 targeting CD19 for B cell driven autoimmune diseases. The deal, valued at up to 2.4 billion dollars in cash including milestone

Read More
Pharma & Biotech

CREATE’s in vivo CAR-T achieves full B cell depletion and repeat dosing in primates

CREATE Medicines shows redosable B cell depletion in primates with in vivo CAR-T platform. Find out what this means for autoimmune and oncology therapy.

Read More